Published in J Immunol Methods on January 26, 1987
Dynamics of the cellular and humoral components of the inflammatory response elicited in skin blisters in humans. J Clin Invest (1992) 1.16
Editorial: will the real neutrophil please stand up? J Leukoc Biol (2011) 0.85
Modified skin window technique for the extended characterisation of acute inflammation in humans. Inflamm Res (2007) 0.84
Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. Ann Surg (2002) 0.82
Novel translational model of resolving inflammation triggered by UV-killed E. coli. J Pathol Clin Res (2016) 0.77
Evaluation of the effect of azapropazone on neutrophil migration in anaesthetized swine using a multichamber blister suction technique. Br J Pharmacol (1990) 0.75
Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) (2000) 7.17
Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med (1999) 5.82
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) (2000) 4.45
The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med (1995) 4.25
The regulatory role of divalent cations in human granulocyte chemotaxis. Evidence for an association between calcium exchanges and microtubule assembly. J Cell Biol (1974) 4.10
Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med (2000) 3.77
Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis (1982) 3.36
Structural analysis of human neutrophil migration. Centriole, microtubule, and microfilament orientation and function during chemotaxis. J Cell Biol (1977) 3.33
Current concepts: immunology. Neutrophils in human diseases. N Engl J Med (1987) 3.29
Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science (1990) 3.15
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
Role of secretory events in modulating human neutrophil chemotaxis. J Clin Invest (1978) 2.59
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis (1998) 2.53
Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis (1990) 2.52
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
The selective eosinophil chemotactic activity of histamine. J Exp Med (1975) 2.45
Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest (1975) 2.40
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science (1989) 2.39
Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol (1986) 2.36
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med (2000) 2.26
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Impact of the regulatory loci agr, sarA and sae of Staphylococcus aureus on the induction of alpha-toxin during device-related infection resolved by direct quantitative transcript analysis. Mol Microbiol (2001) 2.20
Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol (1979) 2.20
Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest (1984) 2.11
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
Granulocyte function in the Chediak-Higashi syndrome of mice. Blood (1974) 2.04
Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) (1998) 2.03
Spinal epidural abscess in clinical practice. QJM (2007) 2.00
Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science (1988) 2.00
Use of lipophilic probes of membrane potential to assess human neutrophil activation. Abnormality in chronic granulomatous disease. J Clin Invest (1980) 1.97
Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis (1978) 1.97
IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol (1990) 1.94
Serum lipids in infection. N Engl J Med (1969) 1.93
Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med (1989) 1.93
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest (1979) 1.85
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J (2010) 1.83
Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis (1999) 1.82
Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis (1992) 1.81
Separation and functional characterization of human neutrophil subpopulations. Blood (1978) 1.80
NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med (1983) 1.76
Degranulating stimuli increase the availability of receptors on human neutrophils for the chemoattractant f-met-leu-phe. J Immunol (1980) 1.74
Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest (1974) 1.69
The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly (2008) 1.69
Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect (2006) 1.66
Interaction of chemotactic factors with human macrophages. Induction of transmembrane potential changes. J Cell Biol (1977) 1.64
Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. J Clin Invest (1988) 1.63
Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin Infect Dis (1995) 1.63
Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood (1982) 1.62
Interaction of chemotactic factors with human polymorphonuclear leukocytes: studies using a membrane potential-sensitive cyanine dye. J Membr Biol (1980) 1.62
The differential mobilization of human neutrophil granules. Effects of phorbol myristate acetate and ionophore A23187. Am J Pathol (1977) 1.60
Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection (2004) 1.58
Correlation of human neutrophil secretion, chemoattractant receptor mobilization, and enhanced functional capacity. J Immunol (1982) 1.58
Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun (1996) 1.57
Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J (2010) 1.57
Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis (1990) 1.55
Spleen-derived mononuclear cell chemotactic factor in malaria infections: a possible mechanism for splenic macrophage accumulation. J Immunol (1977) 1.53
Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med (1990) 1.52
In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother (1995) 1.50
Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis (1990) 1.49
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
A functional differentiation of human neutrophil granules: generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products. J Immunol (1977) 1.47
The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion (2010) 1.45
Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med (1999) 1.44
Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother (1991) 1.44
Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med (1991) 1.44
Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis (1995) 1.43
Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV-seropositive narcotic drug users. AIDS (1996) 1.42
Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. J Clin Invest (1986) 1.41
Degranulating stimuli decrease the neagative surface charge and increase the adhesiveness of human neutrophils. J Clin Invest (1980) 1.41
Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest (1985) 1.41
Infectious complications in drug addicts: seven-year review of 269 hospitalized narcotics abusers in Switzerland. Rev Infect Dis (1989) 1.40
Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis (1988) 1.38
Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem (1990) 1.38
Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother (1998) 1.37
Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother (1994) 1.37
Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum (1976) 1.36
Human neutrophil heterogeneity exists, but is it meaningful? Blood (1984) 1.35
Immunochemical evidence for a novel pertussis toxin substrate in human neutrophils. J Biol Chem (1986) 1.33
Deactivation of human neutrophil chemotaxis by chemoattractants: effect on receptors for the chemotactic factor f-Met-Leu-Phe. J Immunol (1981) 1.33
Human neutrophils contain an intracellular pool of putative receptors for the chemoattractant N-formyl-methionyl-leucyl-phenylalanine. Blood (1983) 1.32
Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A (1988) 1.31
Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol (1978) 1.29
Broad-range PCR in selected episodes of prosthetic joint infection. Infection (2009) 1.29
The hyperimmunoglobulin E recurrent-infection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) (1983) 1.28
Leucocyte chemotaxis: physiological considerations and abnormalities. Clin Haematol (1975) 1.28
Adaptation of human neutrophil responsiveness to the chemoattractant N-formylmethionylleucylphenylalanine. Heterogeneity and/or negative cooperative interaction of receptors. J Biol Chem (1982) 1.28
Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother (1998) 1.27
Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis (1993) 1.27
Chemotactic activity in dialyzable transfer factor. Proc Natl Acad Sci U S A (1974) 1.26
Human neutrophil heterogeneity identified using flow microfluorometry to monitor membrane potential. J Clin Invest (1981) 1.26
Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med (1998) 1.26